198 related articles for article (PubMed ID: 23818777)
21. RGD(Arg-Gly-Asp) internalized docetaxel-loaded pH sensitive liposomes: Preparation, characterization and antitumor efficacy in vivo and in vitro.
Zuo T; Guan Y; Chang M; Zhang F; Lu S; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2016 Nov; 147():90-99. PubMed ID: 27497073
[TBL] [Abstract][Full Text] [Related]
22. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
23. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
[TBL] [Abstract][Full Text] [Related]
24. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
25. Integrin αvβ3 and LHRH Receptor Double Directed Nano-Analogue Effective Against Ovarian Cancer in Mice Model.
Qi N; Zhou X; Ma N; Zhang J; Wang Z; Zhang X; Li A
Int J Nanomedicine; 2024; 19():3071-3086. PubMed ID: 38562611
[TBL] [Abstract][Full Text] [Related]
26. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.
Pietras K; Stumm M; Hubert M; Buchdunger E; Rubin K; Heldin CH; McSheehy P; Wartmann M; Ostman A
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3779-87. PubMed ID: 14506171
[TBL] [Abstract][Full Text] [Related]
27. Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections.
Negishi Y; Hamano N; Sato H; Katagiri F; Takatori K; Endo-Takahashi Y; Kikkawa Y; Nomizu M
Biol Pharm Bull; 2018; 41(7):1107-1111. PubMed ID: 29962407
[TBL] [Abstract][Full Text] [Related]
28. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
29. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo.
Kluza E; Jacobs I; Hectors SJ; Mayo KH; Griffioen AW; Strijkers GJ; Nicolay K
J Control Release; 2012 Mar; 158(2):207-14. PubMed ID: 22079810
[TBL] [Abstract][Full Text] [Related]
30. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.
Chen CW; Lu DW; Yeh MK; Shiau CY; Chiang CH
Int J Nanomedicine; 2011; 6():2567-80. PubMed ID: 22128247
[TBL] [Abstract][Full Text] [Related]
31. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.
Chen Z; Deng J; Zhao Y; Tao T
Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235
[TBL] [Abstract][Full Text] [Related]
32. Dual-targeting liposomes with active recognition of GLUT
Pu Y; Zhang H; Peng Y; Fu Q; Yue Q; Zhao Y; Guo L; Wu Y
Eur J Med Chem; 2019 Dec; 183():111720. PubMed ID: 31553933
[TBL] [Abstract][Full Text] [Related]
33. RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis.
Pu CY; Xu HM; Hu JL; Zheng H; Huang XF; Zhang C; Yang YJ; Li YB
Anticancer Drugs; 2012 Sep; 23(8):788-802. PubMed ID: 22555196
[TBL] [Abstract][Full Text] [Related]
34. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
Li C; Shen J; Wei X; Xie C; Lu W
J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
36. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
[TBL] [Abstract][Full Text] [Related]
37. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
Rangger C; Helbok A; von Guggenberg E; Sosabowski J; Radolf T; Prassl R; Andreae F; Thurner GC; Haubner R; Decristoforo C
Int J Nanomedicine; 2012; 7():5889-900. PubMed ID: 23226020
[TBL] [Abstract][Full Text] [Related]
38. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
39. The anticancer properties and mechanism of action of tablysin-15, the RGD-containing disintegrin, in breast cancer cells.
Deng Z; Chai J; Zeng Q; Zhang B; Ye T; Chen X; Xu X
Int J Biol Macromol; 2019 May; 129():1155-1167. PubMed ID: 30660566
[TBL] [Abstract][Full Text] [Related]
40. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
